targeted rna-sequencing for the quantification of mrd in aml
Published 5 years ago • 55 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
0:55
the role of rna modifications in mds and aml
-
1:40
updates on the use of molecular monitoring to detect mrd in aml
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
1:03
personalizing aml treatment by targeting mrd mutations
-
1:36
targeted therapy for aml
-
5:15
impact of mmrd and eln genetic classification in outcomes for patients with aml underoging allohct
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
4:31
limitations of targeted therapy for aml
-
8:46
aml risk stratification: cytogenetics and mutational analysis - part 1
-
46:40
roles of rna in gene regulation
-
1:31:30
2021 new and emerging treatment options: aml and minimal residual disease in blood cancers
-
2:46
targeted therapies available for the treatment of patients with aml
-
2:18
targeted vs. broader agents for maintenance in aml
-
19:31
utilizing mrd for aml in the clinical setting
-
0:49
treatment avenues for patients with r/r flt3-mutated aml: optimizing flt3 inhibitors
-
1:05
the importance of using mrd to guide treatment decisions in all
-
10:40
the impact of donor kir genotypes on allosct outcomes in aml/mds, and the value of biobanks
-
3:15
using targeted therapies to optimize transplant outcomes in aml
-
4:55
checkpoint inhibitor combination approaches for aml/mds: an update
-
1:56
mrd negativity in npm1-mutated aml: the influence of co-occurring mutations and flag-ida induction
-
5:01
treatment options for high-risk aml
-
3:24
molecular profiling to determine treatment for all and aml